ENZC.US Enzolytics Inc
- Market cap
- USD 2.42M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ENZC.US undervalued?
Graham numberThe Graham number of Enzolytics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enzolytics Inc fundamental analysis
No fundamental analysis for Enzolytics Inc yet.
Enzolytics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enzolytics Inc
Enzolytics, Inc. a drug development company, focuses on the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. It's patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal an…
Full company profileEnzolytics Inc financial statements
Enzolytics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 190K | 5.00K | - | - | 200K | - | 52.8K | - | - |
| Gross Profit | -18.8K | -551K | -11.8K | -17.0K | -17.0K | 183K | -22.1K | 30.7K | -22.1K | -5.52K |
| Operating Income | -64.0K | -816K | -1.71M | -662K | -3.30M | -1.41M | -2.90M | -2.15M | -357K | -83.0K |
| EBITDA | -45.3K | 327K | -1.69M | 1.06M | -3.29M | -612K | -2.88M | -2.12M | -335K | -77.5K |
| Net Income | -550K | -57.3K | -1.76M | 920K | -3.48M | -669K | -2.94M | -2.18M | -394K | -92.2K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 55.3K | 3.31M | 5.61M | 5.60M | 568K | 3.24M | 2.27M | 362M | 202M | 202M |
| Total Liabilities | 1.70M | 7.15M | 5.49M | 6.95M | 5.94M | 5.53M | 5.59M | 365M | 320M | 320M |
| Shareholders' Equity | -1.64M | -3.85M | 122K | -1.35M | -5.37M | -2.29M | -3.32M | -3.56M | -119M | -119M |
| Cash & Short-term Investments | - | 132.00 | 142.00 | 2.09K | 560K | 2.28M | 554K | 360M | 200M | 200M |
| Total Debt | 270K | 418K | 565K | 693K | 1.11M | 1.35M | 1.18M | 996K | 996K | 996K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -454K | 4.89M | -3.24M | -2.24K | -491K | -1.31M | -2.66M | -880K | -563K | - |
| Capital Expenditure | 18.5K | 18.5K | 0.00 | 0.00 | 4.00 | 166K | 0.00 | 3.00 | 0.00 | - |
| Free Cash Flow | -454K | 4.87M | -3.24M | -2.24K | -491K | -1.47M | -2.66M | -880K | -563K | - |
| Ratios | ||||||||||
| ROE | - | - | -1,437.2% | - | - | - | - | - | - | - |
| ROA | -994.0% | -1.7% | -31.3% | 16.4% | -612.4% | -20.7% | -129.7% | -0.6% | -0.2% | 0.0% |
| Net Profit Margin | - | -30.1% | -35,160.0% | - | - | -334.5% | - | -4,123.1% | - | - |
| Debt to Equity | - | - | 4.62x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enzolytics Inc dividends
Enzolytics Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:500 on Feb 7, 2013.
Who owns Enzolytics Inc
Ownership data of Enzolytics Inc is not available yet.
Enzolytics Inc company profile
- Company name
- Enzolytics Inc
- Ticker
- ENZC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1101 Raintree Circle, Allen, TX, United States, 75013
- Phone
- 972 292 9414
- Website
- enzolytics.com
About Enzolytics Inc
Enzolytics, Inc. a drug development company, focuses on the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. It's patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralize the HIV virus. Enzolytics, Inc. is based in Allen, Texas.
Enzolytics Inc management
4- Mr. Harry H. Zhabilov Jr., BSc, McS ScienceCSO & Chairman · born 1967
- Steven SharaburaChief Executive Officer
- Mr. Charles S. CotropiaPresident & Director
- Diana ZhabilovChief Financial Officer